Cerebral (Fatal) Malaria - Pipeline Review, H2 2016

  • ID: 4030245
  • Drug Pipelines
  • 37 pages
  • Global Markets Direct
1 of 5
Cerebral (Fatal) Malaria - Pipeline Review, H2 2016

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Cerebral (Fatal) Malaria - Pipeline Review, H2 2016, provides an overview of the Cerebral (Fatal) Malaria (Infectious Disease) pipeline landscape.

Cerebral malaria is the most dangerous and life-threatening form of malaria that affects the brain. It is caused by plasmodium falciparum, a protozoan parasite. Plasmodium gets transmitted to human via infected mosquito bites.Symptoms include fever, head ache, muscle pain, low blood pressure, coma and convulsions. Treatment includes antimalarial, antiseizure and anti inflammatory medications.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Cerebral (Fatal) Malaria - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Cerebral (Fatal) Malaria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cerebral (Fatal) Malaria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cerebral (Fatal) Malaria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 4 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Cerebral (Fatal) Malaria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cerebral (Fatal) Malaria (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Cerebral (Fatal) Malaria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cerebral (Fatal) Malaria (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cerebral (Fatal) Malaria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cerebral (Fatal) Malaria (Infectious Disease)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cerebral (Fatal) Malaria (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cerebral (Fatal) Malaria (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5
Introduction

Cerebral (Fatal) Malaria Overview

Therapeutics Development

Pipeline Products for Cerebral (Fatal) Malaria - Overview

Pipeline Products for Cerebral (Fatal) Malaria - Comparative Analysis

Cerebral (Fatal) Malaria - Therapeutics under Development by Companies

Cerebral (Fatal) Malaria - Therapeutics under Investigation by Universities/Institutes

Cerebral (Fatal) Malaria - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Cerebral (Fatal) Malaria - Products under Development by Companies

Cerebral (Fatal) Malaria - Products under Investigation by Universities/Institutes

Cerebral (Fatal) Malaria - Companies Involved in Therapeutics Development

Callaghan Innovation Research Ltd

Eisai Co Ltd

Lipocure Ltd

Cerebral (Fatal) Malaria - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

E-6446 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

malaria vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

malaria vaccine 6 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

methylprednisolone sodium phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

neuregulin-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RRX-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Hypoxanthine Phosphoribosyltransferase for Malaria - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cerebral (Fatal) Malaria - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Cerebral (Fatal) Malaria, H2 2016

Number of Products under Development for Cerebral (Fatal) Malaria - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Cerebral (Fatal) Malaria - Pipeline by Callaghan Innovation Research Ltd, H2 2016

Cerebral (Fatal) Malaria - Pipeline by Eisai Co Ltd, H2 2016

Cerebral (Fatal) Malaria - Pipeline by Lipocure Ltd, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Cerebral (Fatal) Malaria - Dormant Projects, H2 2016

List of Figures:

Number of Products under Development for Cerebral (Fatal) Malaria, H2 2016

Number of Products under Development for Cerebral (Fatal) Malaria - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Callaghan Innovation Research Ltd
  • Eisai Co Ltd
  • Lipocure Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll